Pharmacokinetic/pharmacodynamic predictors of clinical potency for hepatitis C virus nonnucleoside polymerase and protease inhibitors

Antimicrobial Agents and Chemotherapy

Volumn 56, Issue 6, 2012, Pages 3144-3156

  Reddy, Micaela B ^a   Morcos, Peter N ^a   Le Pogam, Sophie ^a   Ou, Ying ^b,d   Frank, Karl ^a   Lave, Thierry ^c   Smith, Patrick ^a   Roche, Hoffmann La ^a,b,c  

^a HOFFMANN LA ROCHE INC   (United States)

^b ROCHE BIOSCIENCE   (United States)

^c F HOFFMANN LA ROCHE LTD   (Switzerland)

^d THERAVANCE INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABT 072; ABT 333; ABT 450; ACH 1625; ANTIVIRUS AGENT; ASUNAPREVIR; BOCEPREVIR; DANOPREVIR; FALDAPREVIR; FILIBUVIR; GS 9256; GS 9451; IDX 320; IDX 375; MK 3281; MK 5172; NARLAPREVIR; NONNUCLEOSIDE POLYMERASE INHIBITOR; PROTEINASE INHIBITOR; RITONAVIR; SETROBUVIR; SIMEPREVIR; TEGOBUVIR; TELAPREVIR; UNCLASSIFIED DRUG; VANIPREVIR; VCH 222;

ANIMAL EXPERIMENT; ARTICLE; CHIMPANZEE; CHRONIC HEPATITIS; DOG; DRUG BLOOD LEVEL; DRUG MEGADOSE; DRUG POTENCY; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; LIVER; MONOTHERAPY; MOUSE; NONHUMAN; PHARMACODYNAMICS; PLASMA; PREDICTION; PRIMATE; PRIORITY JOURNAL; RAT; SPECIES COMPARISON; TREATMENT OUTCOME;

ANTIVIRAL AGENTS; HEPACIVIRUS; HUMANS; MODELS, THEORETICAL; PROTEASE INHIBITORS;

EID: 84861127035     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.06283-11     Document Type: Article

References (75)

1. Bavisotto L, et al. 2007. Antiviral, pharmacokinetic and safety data for GS-9190, a non-nucleoside HCV NS5B polymerase inhibitor, in a phase-1 trial inHCVgenotype 1 infected patients. 58th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD), 2 to 6 November 2007, Boston, MA. http://www.natap.org/2007/AASLD/AASLD-39.htm. Accessed 14 March 2011.
2. Bondy SS, Oare DA, Tse WC. June 2011. Pyridazine compound and use thereof. US patent 7,956,184.
3. Brainard DM, et al. 2009. Safety and antiviral activity of NS5B polymerase inhibitor MK-3281 in genotype 1 and 3 HCV-infected patients. 60th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD), 30 October to 3 November 2009, Boston, MA. http://www.natap.org/2009/ AASLD/AASLD-23.htm. Accessed 14 March 2011.
4. Brass CA, et al. 2011. Sustained virologic response and boceprevir resistance- associated variants observed in patients infected with HCV genotype 1a/1b when treated with boceprevir plus peginterferon alpha-2b/ ribavirin: SVR rates among patients with G1b virus were consistently higher than G1a patients in both SPRINT-2 and RESPOND-2. The International Liver Congress 2011, 46th Annual Meeting of the European Association for the Study of the Liver (EASL), 30 March to 3 April 2011, Berlin, Germany. http://www.natap.org/2011/EASL/EASL-96. htm. Accessed 20 October 2011.
5. Chauret N, et al. 2009. Preclinical pharmacokinetic and ADME characterization of VCH-222, a novel non-nucleoside HCV NS5B polymerase inhibitor from Vertex/ViroChem. The International Liver Congress 2009, 44th Annual Meeting of the European Association for the Study of the Liver (EASL), 22 to 26 April 2009, Copenhagen, Denmark. http://www.natap.org/2009/EASL/EASL-65. htm. Accessed 8 June 2011.
6. Chen KX, Njoroge FG. 2010. The journey to the discovery of boceprevir: an NS3-NS4HCVprotease inhibitor for the treatment of chronic hepatitis C. Prog. Med. Chem. 49:1-36.
7. Chu H-M, McNair L, Purdy S. 2004. Results of a phase I single-dose escalation study of the hepatitis C protease inhibitor VX-950 in healthy volunteers, abstr LB 20. Hepatology 40(Suppl 1):735A.
8. Cooper C, Larouche R, Bourgault B, Chauret N, Proulx L. 2009. Safety, tolerability and pharmacokinetics of theHCVpolymerase inhibitor VCH- 222 following single dose administration in healthy volunteers and antiviral activity in HCV-infected individuals. The International Liver Congress 2009, 44th Annual Meeting of the European Association for the Study of the Liver (EASL) 22 to 26 April 2009, Copenhagen, Denmark. http://www.natap.org/2009/EASL/ EASL-48.htm. Accessed 8 June 2011.
9. Corsa A, et al. 2011. Preclinical properties of the novel HCV NS3 protease inhibitor GS-9451. The International Liver Congress 2011, 46th Annual Meeting of the European Association for the Study of the Liver (EASL), 30 March to 3 April 2011, Berlin, Germany. http://www.hivandhepatitis.com/2011- conference/easl2011/posters/corsa.pdf. Accessed 23 August 2011.
10. de Bruijne J, et al. 2010. Phase I study in healthy volunteers and patients with IDX375, a novel non-nucleoside HCV polymerase inhibitor. 61st Annual Meeting of the American Association for the Study of Liver Diseases (AASLD), 30 October to 3 November 2010, Boston, MA. http://www.natap.org/2010/ AASLD/AASLD-93.htm. Accessed 14 March 2011.
11. Detishin V, et al. 2011. Pharmacokinetics, pharmacodynamics, safety and tolerability of ACH-1625 (HCV NS3 protease inhibitor) inHCVgenotype 1 infection. The International Liver Congress 2011, 46th Annual Meeting of the European Association for the Study of the Liver (EASL), 30 March to 3 April 2011, Berlin, Germany. http://www.natap.org/2011/EASL/EASL-82.htm. Accessed 23 August 2011.
12. Dumas E, et al. 2010. Pharmacokinetics of the HCV polymerase inhibitor ABT-072 following single and multiple dosing in healthy adult volunteers. The International Liver Congress 2010, 45th Annual Meeting of the European Association for the Study of the Liver (EASL), 14 to 18 April 2010, Vienna, Austria. http://www.natap.org/2010/EASL/EASL-63.htm. Accessed 9 March 2011.
13. Food and Drug Administration. 2010. Guidance for industry. Chronic hepatitis C virus infection: developing direct-acting antiviral agents for treatment. Draft guidance, September 2010. U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER), Silver Spring, Maryland. http://www.fda.gov/downloads/drugs/ guidancecomplianceregulatoryinformation/guidances/UCM225333.pdf. Accessed 3 October 2011.
14. Forestier N, et al. 2011. Treatment of chronic hepatitis C patients with the NS3/4A protease inhibitor danoprevir (ITMN-191/RG7227) leads to robust reductions in viral RNA: a phase 1b multiple ascending dose study. J. Hepatol. 54:1130-1136.
15. Gane EJ, et al. 2011. Antiviral activity, safety, and pharmacokinetics of danoprevir/ritonavir plus PEG-IFN α-2a/RBV in hepatitis C patients. J. Hepatol. 55:972-979.
16. Gaultier IA, et al. 2011. 12-Week effiacy [sic] and safety of ABT-072 or ABT-333 with pegylated interferon + ribavirin, following 3-day mono-therapy in genotype 1 HCV-infected treatment-naïve subjects. (APASL), 17 to 20 February 2011, Bangkok, Thailand. http://www.natap.org/2011/APSL/APSL-02.htm. Accessed 7 March 2011.
17. Good SS, et al. 2009. Preclinical pharmacokinetic and safety profile of IDX375, a novel and potent non-nucleoside HCV polymerase inhibitor. The International Liver Congress 2009, 44th Annual Meeting of the European Association for the Study of the Liver (EASL), 22 to 26 April 2009, Copenhagen, Denmark. http://www.hivandhepatitis.com/2009icr/easl/pdf/IDX375-Poster-Handout- EASL09-FINAL.pdf. Accessed 28 September 2011.
18. Good SS, et al. 2010. Pharmacokinetic and safety profile of IDX320, a novel and potent HCV protease inhibitor. The International Liver Congress 2010, 45th Annual Meeting of the European Association for the Study of the Liver (EASL), 14 to 18 April 2010, Vienna, Austria. http://www.idenix.com/hcv/ IDX320PK-EASL-2010-handout-FINAL.pdf. Accessed 2 September 2011.
19. Guedj J, Bazzoli C, Neumann AU, Mentre F. 2011. Design evaluation and optimization for models of hepatitis C viral dynamics. Stat. Med. 30:1045-1056.
20. Hammond JL, et al. 2008. Antiviral activity of the HCV polymerase inhibitor PF-00868554 administered as monotherapy in HCV genotype 1 infected subjects. 59th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD), 31 October to 1 November 2008, San Francisco, CA. http://www.natap.org/2008/AASLD/AASLD-18.htm. Accessed 24 March 2011.
21. Huang M, et al. 2010. Antiviral activity, combination and resistance of ACH-1625, a potentHCVNS3 protease inhibitor. The International Liver Congress 2010, 45th Annual Meeting of the European Association for the Study of the Liver (EASL), 14 to 18 April 2010, Vienna, Austria. http://www.natap.org/2010/EASL/ EASL-70.htm. Accessed 2 September 2011.
22. Idenix press release. 2011. IDX375, an HCV non-nucleoside polymerase inhibitor. Idenix, Cambridge, MA. http://www.dailymarkets.com/stock/2011/02/28/ idenix-pharmaceuticals-reports-fourth-quarter-and-year-end-2010-financial- results/. Accessed 14 March 2011.
23. Itakura J, et al. 2011. Changes in hepatitis C viral load during first 14 days can predict the undetectable time point of serum viral load by pegylated interferon and ribavirin therapy. Hepatol. Res. 41:217-224.
24. Johnson TN, Boussery K, Rowland-Yeo K, Tucker GT, Rostami- Hodjegan A. 2010. A semi-mechanistic model to predict the effects of liver cirrhosis on drug clearance. Clin. Pharmacokinet. 49:189-206.
25. Kempf D, et al. 2010. Pharmacokinetic enhancement with ritonavir: more than it seems? 5th International Workshop on Clinical Pharmacology of Hepatitis Therapy, 23 to 24 June 2010, Boston, MA. http://regist2.virology-education.com/ 5thHEP-PK/docs/14-Kempf.pdf. Accessed 16 November 2011.
26. Klein CE, et al. 2009. Safety, tolerability, pharmacokinetics and antiviral activity of the HCV polymerase inhibitor ABT-072 following single and multiple dosing in healthy adult volunteers and two days of dosing in treatment-naïveHCVgenotype 1-infected subjects. HEP DART 2009, 6 to 10 December 2009, Kohala Coast, HI. http://www.natap.org/2009/hepDART/hepDART-01. htm. Accessed 9 November 2011.
27. Klein E, Menon RM, Cohen DE, Awni WM, Bernstein BM. 2009. Pharmacokinetics of a polymerase inhibitor, ABT-333, in treatment-naïve HCV genotype 1-infected subjects following treatment with 2 days of ABT-333 followed by 26 days of ABT-333 plus pegylated interferon and ribavirin. HEP DART 2009, 6 to 10 December 2009, Kohala Coast, HI. http://www.natap.org/2009/ hepDART/hepDART-04.htm. Accessed 10 November 2011.
28. Konnick EQ, Erali M, Ashwood ER, Hillyard DR. 2002. Performance characteristics of theCOBASAmplicor HepatitisCVirus (HCV) Monitor, version 2.0, international unit assay and the National Genetics Institute HCV Superquant assay. J. Clin. Microbiol. 40:768-773.
29. Kuntzen T, et al. 2008. Naturally occurring dominant resistance mutations to hepatitis C virus protease and polymerase inhibitors in treatmentnaïve patients. Hepatology 48:1769-1778.
30. la Porte C. 2008. Inhibitory quotient in HIV pharmacology. Curr. Opin. HIV AIDS 3:283-287.
31. Lallos LB, et al. 2010. In vitro antiviral activity of IDX320, a novel and potent macrocyclic HCV protease inhibitor. The International Liver Congress 2010, 45th Annual Meeting of the European Association for the Study of the Liver (EASL), 14 to 18 April 2010, Vienna, Austria. http://www.natap.org/2010/EASL/ EASL-21.htm. Accessed 2 September 2011.
32. Larrey D, et al. 2009. BI 207127 is a potent HCV RNA polymerase inhibitor during 5 days monotherapy in patients with chronic hepatitis C. 60th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD), 30 October to 3 November 2009, Boston, MA. http://www.natap.org/2009/AASLD/AASLD- 10.htm. Accessed 15 March 2011.
33. Lawitz E, et al. 2010. Initial antiviral activity of the HCV NS3 protease inhibitor ABT-450 when given with low-dose ritonavir as 3-day monotherapy: preliminary results of study M11-602 in genotype 1 (GT1) HCVinfected treatment-naïve subjects. 61st Annual Meeting of the American Association for the Study of Liver Diseases (AASLD), 29 October to 2 November 2010, Boston, MA. http://www.hivandhepatitis.com/2010-conference/aasld/posters/lawitz2.pdf. Accessed 10 June 2011.
34. Lawitz E, et al. 2010. Three-day, dose-ranging study of the HCV NS3 protease inhibitor GS-9451. 61st Annual Meeting of the American Association for the Study of Liver Diseases (AASLD), 29 October to 2 November 2010, Boston, MA. http://www.natap.org/2010/AASLD/AASLD-44.htm. Accessed 2 September 2011.
35. Lawitz E, et al. 2010. Dose-ranging, three-day monotherapy study of the HCV NS3 protease inhibitor GS-9256. The International Liver Congress 2010, 45th Annual Meeting of the European Association for the Study of the Liver (EASL), 14 to 18 April 2010, Vienna, Austria. http://www.natap.org/2010/EASL/EASL-08.htm. Accessed 2 September 2011.
36. Lawitz E, et al. 2009. Antiviral activity of ANA598, a potent nonnucleoside polymerase inhibitor, in chronic hepatitis C patients. The International Liver Congress 2009, 44th Annual Meeting of the European Association for the Study of the Liver (EASL), 22 to 26 April 2009, Copenhagen, Denmark. http://www.anadyspharma.com/products-in-development/pdf/ANA598. EASL2009.pdf. Accessed 18 October 2011.
37. Lawitz E, et al. 2008. Safety, tolerability and antiviral activity of MK-7009, a novel inhibitor of the hepatitis C virus NS3/4A protease, in patients with ChronicHCVgenotype 1 infection. 59th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD), 31 October to 1 November 2008, San Francisco, CA. http://www.natap.org/2008/AASLD/AASLD-09.htm. Accessed 2 September 2011.
38. Le Pogam S, et al. 2008. Existence of hepatitis C virus NS5B variants naturally resistant to non-nucleoside, but not to nucleoside, polymerase inhibitors among untreated patients. J. Antimicrob. Chemother. 61:1205-1216.
39. Lin T, et al. 2009. In vitro activity and preclinical profile of TMC435350, a potent hepatitis C virus protease inhibitor. Antimicrob. Agents Chemother. 53:1377-1385.
40. Reference deleted.
41. Liverton NJ, et al. 2010b. MK-7009, a potent and selective inhibitor of hepatitis C virus NS3/4A protease. Antimicrob. Agents Chemother. 54:305-311.
42. Lok A, et al. 2010. Combination therapy with BMS-790052 and BMS-650032 alone or with pegylated interferon and ribavirin (pegIFN/RBV) results in undetectable HCV RNA through 12 weeks of therapy in HCV genotype 1 null responders. 61st Annual Meeting of the American Association for the Study of Liver Diseases (AASLD), 30 October to 3 November, Boston, MA. http://www.natap.org/2010/AASLD/AASLD-16.htm. Accessed 2 September 2011.
43. Manns MP, et al. 2011. Potency, safety, and pharmacokinetics of the NS3/4A protease inhibitor BI201335 in patients with chronic HCV genotype- 1 infection. J. Hepatol. 54:1114-1122.
44. Manns M, et al. 2008. Safety and antiviral activity of TMC435350 in treatment-naive genotype 1 HCV-infected patients. 59th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD), 31 October to 1 November 2008, San Francisco, CA. http://www.natap.org/2008/AASLD/AASLD-10.htm. Accessed 2 September 2011.
45. McPhee F. 2010. Identification and preclinical profile of the novel HCV NS3 protease inhibitor BMS-650032. The International Liver Congress 2010, 45th Annual Meeting of the European Association for the Study of the Liver (EASL), 30 March to 3 April 2010, Berlin, Germany. http://www.kenes.com/easl2010/posters/ Abstract649.htm. Accessed 2 September 2011.
46. Menon R, et al. 2009. Pharmacokinetics, safety and tolerability of the HCV polymerase inhibitor ABT-333 following multiple ascending doses and effect of coadministration of ketoconazole in healthy subjects. The International Liver Congress 2009, 44th Annual Meeting of the European Association for the Study of the Liver (EASL), 22 to 26 April 2009, Copenhagen, Denmark. http://www.natap.org/2009/EASL/EASL-53.htm. Accessed 14 March 2011.
47. Mo H, et al. 2010. Enhanced in vitro antiviral activity and suppression of resistance by combining GS-9256, a novel protease inhibitor, with GS- 9190, a non-nucleoside NS5B inhibitor. 61st Annual Meeting of the American Association for the Study of Liver Diseases (AASLD), 29 October to 2 November 2010, Boston, MA. http://www.hivandhepatitis.com/2010-conference/aasld/posters/mo.pdf. Accessed 25 August 2011.
48. Monteagudo E, Fonsil, et al. 2010. The metabolism and disposition of a potent inhibitor of hepatitis C virus NS3/4A protease. Xenobiotica 40:826-839.
49. Nakai K, et al. 2008. Decreased expression of cytochromes p450 1A2, 2E1, and 3A4 and drug transporters Na(+)-taurocholate-cotransporting poly-peptide, organic cation transporter 1, and organic anion-transporting peptide-C correlates with the progression of liver fibrosis in chronic hepatitis C patients. Drug Metab. Dispos. 36:1786-1793.
50. Neely MN, Rakhmanina NY. 2011. Pharmacokinetic optimization of antiretroviral therapy in children and adolescents. Clin. Pharmacokinet. 50:143-189.
51. Neumann AU, et al. 1998. Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-alpha therapy. Science 282:103-107. (Pubitemid 28471138)
52. Pasquinelli C, et al. 2009. Safety, tolerability, pharmacokinetics and antiviral activity following single- and multiple-dose administration of BMS-650032, a novel HCV NS3 inhibitor, in subjects with chronic genotype 1 HCV infection. 60th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD), 30 October to 3 November 2009, Boston, MA. http://www.natap.org/2009/AASLD/AASLD-13.htm. Accessed 2 September 2011.
53. Pawlotsky JM, et al. 2000. Standardization of hepatitis C virus RNA quantification Hepatol. 32:654-659.
54. Perni RB, et al. 2006. Preclinical profile of VX-950, a potent, selective, and orally bioavailable inhibitor of hepatitis C virus NS3-4A serine protease. Antimicrob. Agents Chemother. 50:899-909. (Pubitemid 43327793)
55. Petry A, et al. 2010. Safety, tolerability, and pharmacokinetics after single and multiple doses of MK-5172, a novel HCV NS3/4a protease inhibitor with potent activity against known resistance mutants, in healthy subjects. 61st Annual Meeting of the American Association for the Study of Liver Diseases (AASLD), 29 October to 2 November 2010, Boston, MA. http://www.hivandhepatitis. com/2010-conference/aasld/posters/petry2.pdf. Accessed 2 September 2011.
56. Petry A, et al. 2010. Safety and antiviral activity of MK-5172, a novel HCV NS3/4a protease inhibitor with potent activity against known resistance mutants, in genotype 1 and 3 HCV-infected patients. 61st Annual Meeting of the American Association for the Study of Liver Diseases (AASLD), 29 October to 2 November 2010, Boston, MA. http://www.natap.org/2010/AASLD/AASLD-34.htm. Accessed 2 September 2011.
57. Poirier A, et al. 2008. Design, data analysis, and simulation of in vitro drug transport kinetic experiments using a mechanistic in vitro model. Drug Metab. Dispos. 36:2434-2444.
58. Reference deleted.
59. Reesink H, et al. 2009. Safety and antiviral activity of SCH 900518 administered as monotherapy and in combination with peginterferon alfa-2b to naïve and treatment-experienced HCV-1 infected patients. The International Liver Congress 2009, 44th Annual Meeting of the European Association for the Study of the Liver (EASL), 22 to 26 April 2009, Copenhagen, Denmark. http://www.natap.org/2009/EASL/EASL-39.htm. Accessed 2 September 2011.
60. Reesink HW, et al. 2010. Antiviral activity, safety and pharmacokinetics of IDX320, a novel macrocyclic HCV protease inhibitor, in a 3-day proofof-concept study in patients with chronic hepatitis C. 61st Annual Meeting of the American Association for the Study of Liver Diseases (AASLD), 29 October to 2 November 2010, Boston, MA. http://www.natap.org/2010/AASLD/AASLD-92.htm. Accessed 2 September 2011.
61. Reesink HW, et al. 2010. Rapid HCV-RNA decline with once daily TMC435: a phase I study in healthy volunteers and hepatitis C patients. Gastroenterology 138:913-921.
62. Reesink HW, et al. 2006. Rapid decline of viral RNA in hepatitis C patients treated with VX-950: a phase Ib, placebo-controlled, randomized study. Gastroenterology 131:997-1002. (Pubitemid 44498690)
63. Rouzier R, et al. 2011. Activity of danoprevir plus low-dose ritonavir in combination with peginterferon alfa-2a (40KD) plus ribavirin in previous null responders. The International Liver Congress 2011, 46th Annual Meeting of the European Association for the Study of the Liver (EASL), 30 March to 3 April 2011, Berlin, Germany. http://www.natap.org/2011/EASL/EASL-21.htm. Accessed 20 October 2011.
64. Seiwert SD, et al. 2008. Preclinical characteristics of the hepatitis C virus NS3/4A protease inhibitor ITMN-191 (R7227). Antimicrob. Agents Chemother. 52:4432-4441.
65. Shih IH, et al. 2011. Mechanistic characterization of GS-9190 (tegobuvir), a novel nonnucleoside inhibitor of hepatitis C virus NS5B polymerase. Antimicrob. Agents Chemother. 55:4196-4203.
66. Silva M, et al. 2011. Antiviral activity of boceprevir monotherapy in treatment-naive subjects with chronic hepatitis C genotype 2/3. 21st Conference of the Asian Pacific Association for the study of the Liver (APASL), 17 to 20 February, Bangkok, Thailand. http://www.natap.org/2011/APSL/APSL-03.htm. Accessed 2 September 2011.
67. Snoeck E, et al. 2010. A comprehensive hepatitis C viral kinetic model explaining cure. Clin. Pharmacol. Ther. 87:706-713.
68. Stauber K, et al. 2010. Characterization of the hepatoselective distribution of ACH-1625: a potent, clinical stage HCV NS3 protease inhibitor. The International Liver Congress 2010, 45th Annual Meeting of the European Association for the Study of the Liver (EASL), 14 to 18 April 2010, Vienna, Austria. http://www.natap.org/2010/EASL/EASL-69.htm. Accessed 2 September 2011.
69. Thompson PA, et al. 2008. Pathway to selection of a potent, well tolerated development candidate in HCV. http://www.anadyspharma.com/products-in- development/pdf/ICAR-2008-Final.pdf. Accessed 28 June 2011.
70. Tong X, et al. 2010. Preclinical characterization of the antiviral activity of SCH 900518 (narlaprevir), a novel mechanism-based inhibitor of hepatitis C virus NS3 protease. Antimicrob. Agents Chemother. 54:2365-2370.
71. University of California, San Francisco. 2007. Course notes from the 20th annual Pharmacokinetics for Pharmaceutical Scientists course, Department of Biopharmaceutical Sciences, School of Pharmacy, University of California, San Francisco, CA.
72. Watkins WJ, Ray AS, Chong LS. 2010. HCV NS5B polymerase inhibitors. Curr. Opin. Drug Discov. Devel. 13:441-465.
73. White PW, et al. 2010. Preclinical characterization of BI 201335, a C-terminal carboxylic acid inhibitor of the hepatitis C virus NS3-NS4A protease. Antimicrob. Agents Chemother. 54:4611-4618.
74. Wright DH, et al. 2008. Safety, tolerability, and pharmacokinetic data following single- and multiple-dose administration of MK-7009, a hepatitis C virus non-structural 3/4a protease inhibitor, to healthy male subjects. 59th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD), 31 October to 1 November 2008, San Francisco, CA. http://www.natap.org/ 2008/AASLD/AASLD-25.htm. Accessed 2 September 2011.
75. Zeuzem S. 2005. SCH 503034 protease inhibitor monotherapy in hepatitis C virus genotype-1 IFN-a non-responders. 56th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD), 11 to 15 November 2005, San Francisco, CA. http://www.natap.org/2006/HCV/031706-02.htm. Accessed 2 September 2011.